K-REACH Decree Revision takes effect for bioprocess equipment in South Korea, impacting customs clearance, registration, and delivery planning. Learn what exporters and importers must review now.

CPHI & PMEC China 2026 puts single-use bioreactors in focus with 3,600 suppliers, a 37% exhibitor rise, and a new SUT matchmaking hub for global CXO sourcing.

Monoclonal antibodies scale-up can fail on hidden transfer risks in upstream, downstream, analytics, and GMP. Learn the key checkpoints to protect quality and speed commercial readiness.

ASCO 2026 reveals a CGT CDMO surge, with Parallel Mini-bioreactor demand up 210% and early-stage orders shifting to China CXO platforms. See what it means for outsourcing and procurement.

ASCO 2026 signals a surge in cell therapy CMO orders, driven by late-stage CAR-T and TCR-T demand. Discover what it means for CDMOs, bioreactor procurement, and CGT capacity planning.

ASCO 2026 reveals CGT CMO orders surging as bioreactor demand jumps with faster CAR-T and NK approvals. See what supply tightness and Q1 2027 lead times mean for buyers.

FDA QMSR guide update tightens bioreactor export filings for monoclonal antibody systems. Learn the new GMP validation package rules and how exporters can avoid delays.

China’s single-use bioreactor exports jumped 62% in Q1 2026, revealing new opportunities for CDMOs, biologics plants, vaccine centers, and global supply chains.